| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 128,546 | -815 |
| Net change in cash, cash equivalents and restricted cash | 2,729 | -20,627 |
| Cash and cash equivalents at beginning of period | 44,051 | - |
| Cash and cash equivalents at end of period | 46,780 | - |
Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics, Inc. (CMPX)